|
||||||||||||||||||||||
Systematic review and meta-analysis This trial is included in the following systematic reviews and meta-analyses: diabetes - angiotensin renin system blockade - all type of patients diabetes - angiotensin-receptor blockers - all type of patients diabetes - anti hypertensive agent - patients with or without hypertension Related trials ROADMAP, 2010 - olmesartan vs placebo ADVANCE, 2007 - perindopril and indapamide vs placebo LIFE (diabetic subgroup), 2002 - losartan vs atenolol ALLHAT (lisi vs chlor, diabetic subgroup), 2002 - lisinopril vs chlorthalidone IDNT irbesartan, 2001 - Irbesartan vs placebo IPDM, 2001 - irbesartan vs placebo RENAAL, 2001 - losartan vs placebo IDNT (irbesartan vs amlodipine), 2001 - Irbesartan vs amlodipine STOP-2 ACEI (diabetic subgroup), 2000 - ACE inhibitor vs diuretic or beta-blocker STOP-2 (ACEI vs CCB) (diabetic subgroup), 2000 - ACE inhibitor vs CCB HOPE (diabetic subgroup), 2000 - ACE inhibitor vs placebo CAPP (diabetic subgroup), 1999 - captopril vs diuretic or beta-blocker UKPDS 38, 1998 - captopril or atenolol vs control See also: |
Treatments
Patients
Method and design
ResultsNo results available for this trial - no clinical endpoint reported Meta-analysis of all similar trials: angiotensin renin system blockade in diabetes for all type of patients angiotensin-receptor blockers in diabetes for all type of patients anti hypertensive agent in diabetes for patients with or without hypertension Reference(s)
|
|||||||||||||||||||||
(c) 2004-2010 TrialResults-center - All Rights Reserved |